Hansa Biopharma (DB:24H) - Stock Price, News & Analysis

24H Stock Overview

Hansa Biopharma AB (publ), empresa biofarmacéutica, se dedica al desarrollo y comercialización de tratamientos para pacientes con enfermedades inmunológicas raras en Europa y Estados Unidos.

About the company

24H fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Se prevé un crecimiento anual de los ingresos de 40.7%

Risk Analysis

Cotización muy volátil en los últimos 3 meses

Fondos propios negativos

Tiene menos de 1 año de cash runway

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Hansa Biopharma AB (publ) Competitors

Heidelberg Pharma

XTRA:HPHA

€142.1m

2invest

XTRA:2INV

€48.9m

Medigene

XTRA:MDG1

€53.3m

Formycon

XTRA:FYB

€812.4m

Price History & Performance

Summary of all time highs, changes and price drops for Hansa Biopharma
Historical stock prices
Current Share Price	kr2.67
52 Week High	kr4.97
52 Week Low	kr1.71
Beta	1.26
1 Month Change	-1.70%
3 Month Change	24.35%
1 Year Change	-42.19%
3 Year Change	-82.63%
5 Year Change	-87.06%
Change since IPO	-86.93%

Recent updates

Shareholder Returns

	24H	DE Biotechs	DE Market
7D	8.5%	4.5%	-1.3%
1Y	-42.2%	-13.9%	4.1%

Rentabilidad frente al sector: 24H obtuvo unos resultados inferiores a los del sector German Biotechs , que el año pasado arrojó un rendimiento del -23.6%.

Rentabilidad vs. Mercado: 24H obtuvo unos resultados inferiores a los del mercado German, que fue del -1.4% el año pasado.

Price Volatility

Is 24H's price volatile compared to industry and market?
24H volatility
24H Average Weekly Movement	12.4%
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.7%
10% most volatile stocks in DE Market	9.7%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: El precio de las acciones de 24H ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: 24H(14%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de German.

About the Company

Founded	Employees	CEO	Website
2007	168	Søren Tulstrup	https://www.hansabiopharma.com

Hansa Biopharma AB (publ), empresa biofarmacéutica, se dedica al desarrollo y comercialización de tratamientos para pacientes con enfermedades inmunológicas raras en Europa y Estados Unidos. La empresa ofrece Idefirix (imlifidasa), que se dirige y escinde todas las clases de anticuerpos de inmunoglobulina G (IgG) para el tratamiento de desensibilización de pacientes adultos con trasplante renal sensibilizados con una prueba de compatibilidad cruzada positiva. También está desarrollando nuevas enzimas de escisión de inmunoglobulinas para dosificación repetida (NiceR) para el tratamiento de enfermedades autoinmunes, trasplantes y oncología, así como EnzE (Enzyme based antibody Enhancement), una inmunoterapia contra el cáncer.

Hansa Biopharma AB (publ) Fundamentals Summary

How do Hansa Biopharma's earnings and revenue compare to its market cap?
24H fundamental statistics
Market cap	€143.88m
Earnings (TTM)	-€72.12m
Revenue (TTM)	€11.63m

12.4x

P/S Ratio

-2.0x

P/E Ratio

Is 24H overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
24H income statement (TTM)
Revenue	kr134.09m
Cost of Revenue	kr63.14m
Gross Profit	kr70.95m
Other Expenses	kr902.67m
Earnings	-kr831.72m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 18, 2024

Earnings per share (EPS)	-15.79
Gross Margin	52.91%
Net Profit Margin	-620.25%
Debt/Equity Ratio	-503.3%

How did 24H perform over the long term?

See historical performance and comparison

24H Stock Overview

Rewards

Risk Analysis

Hansa Biopharma AB (publ) Competitors

XTRA:HPHA

€142.1m

XTRA:2INV

€48.9m

XTRA:MDG1

€53.3m

XTRA:FYB

€812.4m

Price History & Performance

Recent News & Updates

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (Publ) Announces CFO Changes

No longer forecast to breakeven

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Recent updates

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (Publ) Announces CFO Changes

No longer forecast to breakeven

Full year 2023 earnings released: kr15.83 loss per share (vs kr13.60 loss in FY 2022)

Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Forecast to breakeven in 2026

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Hansa Biopharma Nomination Committee Formed

Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Third quarter 2023 earnings released: kr4.78 loss per share (vs kr3.45 loss in 3Q 2022)

New minor risk - Profitability

New minor risk - Profitability

Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma

Hansa Biopharma AB (publ) to Report Q1, 2024 Results on Apr 17, 2024

Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis

Second quarter 2023 earnings released: kr4.79 loss per share (vs kr3.82 loss in 2Q 2022)

Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation

Hansa Biopharma Announces First Patient Dosed with Imlifidase in a Global Pivotal Phase 3 Trial in Anti-Inaugular Basement Membrane (anti-GBM) Disease

First quarter 2023 earnings released: kr3.92 loss per share (vs kr3.11 loss in 1Q 2022)

Full year 2022 earnings released: kr13.57 loss per share (vs kr12.33 loss in FY 2021)

Hansa Biopharma Announces Planned Departure of Chief Scientific Officer Christian Kjellman

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma AB (publ) Announces Formation of Nomination Committee

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering.

Hansa Biopharma AB (Publ) Announces Positive Reimbursement Decision in Italy for Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation

Hansa Biopharma AB Announces Positive Topline Data from the Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023

Third quarter 2022 earnings released: kr3.45 loss per share (vs kr3.34 loss in 3Q 2021)

Hansa Biopharma AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

The Scottish Medicines Consortium Recommends Use of Hansa Biopharma's Idefirix[®] (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix in Highly Sensitized Kidney Transplant Patients

Second quarter 2022 earnings released: kr3.82 loss per share (vs kr2.98 loss in 2Q 2021)

Hansa Biopharma AB (publ) announced that it has received $70 million in funding from NovaQuest Capital Management, L.L.C.

Hansa Biopharma Announces First Patient Treated in the Post-Authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Appoints Peter Nicklin as A New Member of the Board of Director

NICE Recommends Use of Hansa Biopharma's Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Announces Ulf Wiinberg Not to Stand for Re-Election as Director

Hansa Biopharma Completes Enrollment in Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma Announces Temporary Marketing Authorization in Switzerland for Idefirix (Imlifidase) in Kidney Transplantation

First quarter 2022 earnings released: kr3.11 loss per share (vs kr2.34 loss in 1Q 2021)

Hansa Biopharma Announces U.S. Fda Acceptance of Investigational New Drug (Ind) Application for Phase 3 Study of Imlifidase in Anti-Gbm Disease

Full year 2021 earnings released: kr12.33 loss per share (vs kr9.98 loss in FY 2020)

Hansa Biopharma AB and Medison Pharma Announces Marketing Authorization in Israel for Idefirix for Desensitization Treatment of Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB Announces Grant of Early Access Post Marketing Authorization for its First-In-Class Treatment Idefirix® (imlifidase)

Hansa Biopharma AB Announces Positive Early Access Decision by French Haute Autorité De Santé to Use Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Hansa Biopharma Enrolls First Patient in U.S. Randomized, Controlled Pivotal Trial of imlifidase in Highly Sensitized Kidney Transplant Patients

Third quarter 2021 earnings released: kr3.34 loss per share (vs kr2.77 loss in 3Q 2020)

Hansa Biopharma Announces Reimbursement in the Netherlands of Idefirix[®] (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Independent Chairman of the Board recently bought €110k worth of stock